The estimated Net Worth of Mark L Perry is at least 52.5 百万$ dollars as of 2 April 2024. Mr. Perry owns over 7,000 units of Global Blood Therapeutics stock worth over 7,944,840$ and over the last 21 years he sold GBT stock worth over 43,908,409$. In addition, he makes 613,245$ as Lead Independent Director at Global Blood Therapeutics.
Mark has made over 23 trades of the Global Blood Therapeutics stock since 2003, according to the Form 4 filled with the SEC. Most recently he sold 7,000 units of GBT stock worth 6,215,230$ on 2 April 2024.
The largest trade he's ever made was exercising 175,000 units of Global Blood Therapeutics stock on 6 April 2011 worth over 1,482,250$. On average, Mark trades about 10,733 units every 124 days since 2003. As of 2 April 2024 he still owns at least 116,000 units of Global Blood Therapeutics stock.
You can see the complete history of Mr. Perry stock trades at the bottom of the page.
Mark L. Perry J.D. serves as Lead Independent Director of the Company. From October 2012 to October 2013, Mr. Perry served as an entrepreneur-in-residence at Third Rock Ventures. Since August 2011, he has served on various boards of companies and non-profit organizations. In October 2004, Mr. Perry joined Aerovance, Inc., a biopharmaceutical company, as a director, and he served as president and chief executive officer of Aerovance from February 2007 to October 2011. Prior to that, Mr. Perry served as the senior business adviser of Gilead Sciences, Inc., a biopharmaceutical company, from April 2004 to February 2007 and as an executive officer from May 1994 to April 2004, during which time he served in a variety of capacities, including general counsel, chief financial officer and executive vice president of operations. Earlier in his career, from 1981 to 1994, Mr. Perry served as an attorney at Cooley LLP, and was a partner of the firm from 1987 to 1994. Mr. Perry currently serves on the board of directors of Nvidia Corporation, a visual computing company, as the lead independent director, and MyoKardia, Inc., a biopharmaceutical company, as the non-executive chairman of the board. Mr. Perry received a B.A. in history from the University of California, Berkeley and a J.D. from the University of California, Davis. Mr. Perry’s qualifications to serve on our Board of Directors include more than 30 years of experience serving in professional and management positions in the biotechnology industry, as well as his experience serving on the board of directors (and certain key standing committees) of other biopharmaceutical companies.
As the Lead Independent Director of Global Blood Therapeutics, the total compensation of Mark Perry at Global Blood Therapeutics is 613,245$. There are 13 executives at Global Blood Therapeutics getting paid more, with Ted Love having the highest compensation of 10,097,200$.
Mark Perry is 64, he's been the Lead Independent Director of Global Blood Therapeutics since 2018. There are 4 older and 17 younger executives at Global Blood Therapeutics. The oldest executive at Global Blood Therapeutics Inc. is Willie Brown, 86, who is the Independent Director.
Mark's mailing address filed with the SEC is C/O NVIDIA CORPORATION, 2788 SAN TOMAS EXPRESSWAY, SANTA CLARA, CA, 95051.
Over the last 9 years, insiders at Global Blood Therapeutics have traded over 164,753,446$ worth of Global Blood Therapeutics stock and bought 255,000 units worth 8,595,265$ . The most active insiders traders include Advisors Llcperceptive Life...、Rock Ventures Ii, L.P.Third...、Kevin P Starr. On average, Global Blood Therapeutics executives and independent directors trade stock every 14 days with the average trade being worth of 3,133,144$. The most recent stock trade was executed by Nazila Habibizad on 1 October 2022, trading 1,557 units of GBT stock currently worth 106,639$.
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor) tablets, the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in development to address pain crises associated with the disease, and GBT021601 (GBT601), the company's next generation hemoglobin S polymerization inhibitor. In addition, GBT's drug discovery teams are working on new targets to develop the next wave of treatments for SCD.
Global Blood Therapeutics executives and other stock owners filed with the SEC include: